Pacific Biosciences of California, Inc. (PACB)
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close.
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
PACB Stock Declines Despite Promising HiFi Sequencing Findings
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
PacBio Stock May Gain Following the Collaborated Launch of GutID
PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics
PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.
Why the Market Dipped But Pacific Biosciences of California (PACB) Gained Today
Pacific Biosciences of California (PACB) closed at $2 in the latest trading session, marking a +0.5% move from the prior day.
Reasons to Retain PacBio Stock in Your Portfolio for Now
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight
Ark Invest CEO Cathie Wood is doubling down on genomics.
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term growth given the rapid technological advancements in the genomic market.
PacBio price target lowered to $6 from $7 at Scotiabank
Scotiabank lowered the firm's price target on PacBio to $6 from $7 and keeps an Outperform rating on the shares. The firm lowered its FY24 and FY25 revenue estimates following the company's Q3 update, the analyst tells investors. The firm's longer-term outlook for the company, however, remains intact, believing the company is highly differentiated and the recently accelerated pace of product innovations place the company in a good position for outsized growth.
